Perioperative Pembrolizumab (MK-3475) Plus Cystectomy Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905)

Official Title

A Phase 3 Randomized Study of Cystectomy Plus Perioperative Pembrolizumab Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer (KEYNOTE-905)

Summary:

A global, randomized phase III study to evaluate perioperative pembrolizumab with radical cystectomy + pelvic lymph node dissection (RC+PLND) versus RC+PLND alone in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC).

Trial Description

Primary Outcome:

  • Pathologic Complete Response (pCR) Rate in All Participants
  • Pathologic Complete Response Rate in Participants Whose Tumours Express PD-L1 Combined Positive Score (CPS) ≥10
  • Event-Free Survival (EFS) in All Participants
  • Event-Free Survival in Participants Whose Tumours Express PD-L1, CPS ≥10
Secondary Outcome:
  • Overall Survival (OS) in All Participants
  • Overall Survival in Participants Whose Tumours Express PD-L1, CPS ≥10
  • Disease-Free Survival (DFS) in All Participants
  • Disease-Free Survival in Participants Whose Tumours Express PD-L1, CPS ≥10
  • Pathologic Downstaging (pDS) Rate in All Participants
  • Pathologic Downstaging (pDS) Rate in Participants Whose Tumours Express PD-L1, CPS ≥10
  • Number of Participants Experiencing Adverse Events (AEs)
  • Number of Participants Discontinuing Study Drug Due to Adverse Events (AEs)
  • Number of Participants Experiencing Perioperative Complications

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society